Providing innovative bioinformatic solutions for next-generation sequencing data analysis
We founded AptaIT in 2011, because we believe that the key to exploit the enormous potential of next-generation sequencing is to provide a fast and easy access to data analysis without additional skills in informatics or mathematics. Our team has broad expertise in biochemistry, immunology, physics, and software development to provide you with the information that you really need from next-generation sequencing analysis. Simply “Reduce to the Best!”
We have developed two complimentary software platforms with a first focus on biopanning, SELEX and immunoprofiling: AptaAnalyzerTM for intuitive and user-friendly processing of the most frequent analysis tasks and COMPAS for answering complex and custom-tailored next-generation sequencing analysis questions. Here, you can find out more about our services and software.
AptaIT - Reduce to the Best
Dr. Raymund Buhmann
is an expert in the field of bispecific antibodies and drug development.
He graduated in medical sciences at the University of Munich, Germany in 1994. He received the approbation as a physician in 1996, the ECFMG Certification in 1997, board of Internal Medicine in 2002 and of Hematology and Oncology in 2004. In 2000, he co-founded a Biotech start-up company (NascaCell IP GmbH, Munich, Germany) dedicated to develop small molecule drug candidates for immune disorders, cardiovascular and infectious diseases. Since 2004 he is group leader and since 2009 head of the Clinical cooperative group for Hematopoietic stem cell transplantation (CCG-HCT; HMGU/LMU, Munich) specialized in allogeneic transplantation, adoptive immunotherapy and drug development in a clinical co-operation group (HMGU-LMU, Munich).
Dr. Michael Blank
is an expert in the field of in vitro evolution.
He holds a diploma in chemistry from the Julius-Maximilians-University in Würzburg, Germany. In 2002 he received his PhD in chemistry from the Eberhard-Karls-University in Tübingen, Germany. Within his doctoral thesis, he developed an aptamer-based approach to identify novel target molecules on cells useful as antigens for tumour diagnostics. In 2002, he joined NascaCell IP GmbH (Munich, Germany) and was responsible for the establishment of advanced aptamer in vitro selection strategies (automated and manual strategies). From 2004 on, he headed the department Aptamer Technologies. From 2009 to 2011, Dr. Blank developed bispecific aptamers in the clinical cooperative group for Hematopoietic stem cell transplantation (CCG-HCT; HMGU/LMU, Munich).
Dr. Carsten Gröber
is expert in the field of bioinformatics.
He graduated in physics at University of Würzburg, Germany, in 1999. In his doctoral thesis, he focused on statistical analysis of large correlated data sets already while simulating quantum particle systems on high performance super computers. He joined Infineon/Qimonda 1999 and worked as CAD-Engineer for research and redevelopment topics in the design process of DRAM- and special graphics memory products, as well as tools for dynamic simulation of complete power supply systems of memory design. The acquired expert knowledge in statistics and informatics in general and effective handling of giant datasets in particular enabled him to develop the algorithm to identify enriched binders in large sequence data sets from NGS in 2009.